Group ACYW135 meningococcal polysaccharide vaccine is the product developed independently by Walvax. Walvax obtained the Drug Registration Approval issued by the State Food and Drug Administration on March, 2012 (No.: 2012S00181, Drug Approval No.: Guoyao Zhunzi S20120003). The product was on market officially in December 2012.
This vaccine is made of A, C, Y, W135 meningococcal medium via purification of capsular polysaccharide antigen, adding lactose as stabilizer after purification to make freeze-dried vaccine. The lyophilized vaccine should be white color which can be dissolved completely after adding the colorless diluents (sterile water for injection), clear, colorless liquid appears after reconstitution.
Currently, this product is only recommended for children above 2 years old and the people who are at the high risk of getting this disease to use.
After vaccination, it can make the body to produce humoral immune response to prevent meningococcal disease caused by epidemic Neisseria meningitidis serogroups A, C, Y, and W-135.